智通财经APP讯，迈威生物(688062.SH)发布2025年年度报告，报告期内，公司实现营业收入6.63亿元，同比增长231.62%。归属于上市公司股东的净亏损9.69亿元，归属于上市公司股东的扣除非经常性损益的净亏损9.99亿元，基本每股亏损2.43元。
报告期归属于上市公司股东的净亏损较上年同期减少7,458.56万元，归属于上市公司股东的扣除非经常性损益的净亏损较上年同期减少7,075.02万元，主要系公司与齐鲁制药、DISC的授权许可合同确认收入金额较大，同时药品销售收入增加较多。
报告期经营活动产生的现金流量净额流出较上年同期减少66,622.05万元，主要系本期公司收到齐鲁制药、CALICO、Kalexo技术许可合同首付款及DISC技术许可合同里程碑款金额较大。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.